Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22909373 | 0.76 | AR (0.45) | — | |
| SCHEMBL29729050 | 0.74 | HDAC6 (0.39) | MAOB | |
| SCHEMBL22909262 | 0.74 | HDAC6 (0.39) | MAOB | |
| SCHEMBL29671295 | 0.73 | ALOX5AP (0.41) | MAOBMAPK14 | |
| SCHEMBL22909160 | 0.73 | MAPT (0.36) | ALDH1A1 | |
| SCHEMBL29729048 | 0.73 | CA1 (0.31) | — | |
| SCHEMBL29671271 | 0.72 | SMN1; SMN2 (0.43) | MAOBALDH1A1 | |
| SCHEMBL22909370 | 0.72 | SMN1; SMN2 (0.43) | MAOBALDH1A1 | |
| SCHEMBL22909451 | 0.71 | TSHR (0.48) | MAOB | |
| SCHEMBL20847640 | 0.70 | HDAC6 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021009568-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | MAOB 3430/4885IDO1 4202/4885AGXT 3117/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | MAOB 1549/4885IDO1 4015/4885AGXT 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.